PCSK9 and coronary artery disorder: Take CAD for example, genetically proxied medication of PCSK9 inhibitors was associated with decreased risk, and this association was not modified by BBs compared with the reference group (PCSK9 inhibitors: OR, 0.95; 95%CI, 0.93–0.98; BBs: OR, 0.97; 95%CI, 0.94–0.99; combined: OR, 0.94; 95%CI, 0.91–0.97; P = 0.51 for interaction).